Chenguang Biotech Group Net Assets
Chenguang Biotech Group net assets. Based on the latest financial reports, Chenguang Biotech Group (300138) has net assets worth CN¥3.46 Billion CNY (≈ $505.66 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.62 Billion ≈ $1.41 Billion USD) and total liabilities (CN¥6.16 Billion ≈ $901.48 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Chenguang Biotech Group (300138) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.46 Billion |
| % of Total Assets | 35.94% |
| Annual Growth Rate | 21.6% |
| 5-Year Change | 23.55% |
| 10-Year Change | 125.52% |
| Growth Volatility | 77.06 |
Net Assets of Chenguang Biotech Group (2007–2025)
Net assets of Chenguang Biotech Group from 2007 to 2025. This chart illustrates how Chenguang Biotech Group's net assets have evolved over time, based on quarterly financial data. See 300138 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Chenguang Biotech Group (2007–2025)
The table below shows the annual net assets of Chenguang Biotech Group from 2007 to 2025. For live market cap and overall valuation, see Chenguang Biotech Group market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.44 Billion ≈ $503.23 Million |
+9.01% |
| 2024-12-31 | CN¥3.15 Billion ≈ $461.63 Million |
-10.69% |
| 2023-12-31 | CN¥3.53 Billion ≈ $516.88 Million |
+9.90% |
| 2022-12-31 | CN¥3.21 Billion ≈ $470.32 Million |
+15.47% |
| 2021-12-31 | CN¥2.78 Billion ≈ $407.30 Million |
+35.15% |
| 2020-12-31 | CN¥2.06 Billion ≈ $301.37 Million |
+18.29% |
| 2019-12-31 | CN¥1.74 Billion ≈ $254.77 Million |
+0.05% |
| 2018-12-31 | CN¥1.74 Billion ≈ $254.64 Million |
+7.16% |
| 2017-12-31 | CN¥1.62 Billion ≈ $237.63 Million |
+6.49% |
| 2016-12-31 | CN¥1.52 Billion ≈ $223.15 Million |
+6.85% |
| 2015-12-31 | CN¥1.43 Billion ≈ $208.84 Million |
+41.51% |
| 2014-12-31 | CN¥1.01 Billion ≈ $147.58 Million |
+1.83% |
| 2013-12-31 | CN¥990.39 Million ≈ $144.93 Million |
-0.75% |
| 2012-12-31 | CN¥997.86 Million ≈ $146.02 Million |
+3.01% |
| 2011-12-31 | CN¥968.71 Million ≈ $141.75 Million |
+3.82% |
| 2010-12-31 | CN¥933.05 Million ≈ $136.53 Million |
+342.89% |
| 2009-12-31 | CN¥210.67 Million ≈ $30.83 Million |
+42.41% |
| 2008-12-31 | CN¥147.93 Million ≈ $21.65 Million |
+45.46% |
| 2007-12-31 | CN¥101.70 Million ≈ $14.88 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chenguang Biotech Group's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5768.2% over the analyzed period, indicating profitable operations and earnings retention.
Chenguang Biotech Group Net Assets Breakdown (December 2025)
Chenguang Biotech Group net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.17 Billion | 63.98% |
| Other Components | CN¥1.22 Billion | 36.02% |
| Total Equity | CN¥3.39 Billion | 100.00% |
Chenguang Biotech Group Competitors by Market Cap
The table below lists competitors of Chenguang Biotech Group ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangxi Guotai Civilian
SHG:603977
|
$890.89 Million |
|
Irish Continental Group PLC
IR:IR5B
|
$890.98 Million |
|
Aktia Bank Abp
HE:AKTIA
|
$891.71 Million |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
$891.80 Million |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
$890.67 Million |
|
Sparebanken Sor
OL:SOR
|
$890.43 Million |
|
Hunan Er Kang Pharmaceutical
SHE:300267
|
$890.38 Million |
|
Guangxi Radio and Television Information Network Corp Ltd
SHG:600936
|
$890.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chenguang Biotech Group's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,109,489,222 to 3,389,113,999, a change of 279,624,777 (9.0%).
- Net income of 363,646,100 contributed positively to equity growth.
- Dividend payments of 159,853,625 reduced retained earnings.
- Other comprehensive income decreased equity by 147,460,084.
- Other factors increased equity by 223,292,386.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥363.65 Million | +10.73% |
| Dividends Paid | CN¥159.85 Million | -4.72% |
| Other Comprehensive Income | CN¥-147.46 Million | -4.35% |
| Other Changes | CN¥223.29 Million | +6.59% |
| Total Change | CN¥- | 8.99% |
Book Value vs Market Value Analysis
This analysis compares Chenguang Biotech Group's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 33.36x to 1.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.38 | CN¥12.60 | x |
| 2008-12-31 | CN¥0.54 | CN¥12.60 | x |
| 2009-12-31 | CN¥0.74 | CN¥12.60 | x |
| 2010-12-31 | CN¥2.73 | CN¥12.60 | x |
| 2011-12-31 | CN¥2.26 | CN¥12.60 | x |
| 2012-12-31 | CN¥2.36 | CN¥12.60 | x |
| 2013-12-31 | CN¥2.33 | CN¥12.60 | x |
| 2014-12-31 | CN¥2.39 | CN¥12.60 | x |
| 2015-12-31 | CN¥3.35 | CN¥12.60 | x |
| 2016-12-31 | CN¥2.94 | CN¥12.60 | x |
| 2017-12-31 | CN¥3.18 | CN¥12.60 | x |
| 2018-12-31 | CN¥3.40 | CN¥12.60 | x |
| 2019-12-31 | CN¥3.40 | CN¥12.60 | x |
| 2020-12-31 | CN¥4.07 | CN¥12.60 | x |
| 2021-12-31 | CN¥5.27 | CN¥12.60 | x |
| 2022-12-31 | CN¥5.94 | CN¥12.60 | x |
| 2023-12-31 | CN¥6.52 | CN¥12.60 | x |
| 2024-12-31 | CN¥6.01 | CN¥12.60 | x |
| 2025-12-31 | CN¥7.12 | CN¥12.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chenguang Biotech Group utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.73%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.54%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 2.80x
- Recent ROE (10.73%) is above the historical average (10.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 13.17% | 7.67% | 0.81x | 2.11x | CN¥2.81 Million |
| 2008 | 30.34% | 12.05% | 0.83x | 3.04x | CN¥25.81 Million |
| 2009 | 25.92% | 11.78% | 1.03x | 2.14x | CN¥29.95 Million |
| 2010 | 7.02% | 10.88% | 0.51x | 1.27x | CN¥-27.00 Million |
| 2011 | 7.86% | 7.00% | 0.96x | 1.17x | CN¥-20.48 Million |
| 2012 | 5.92% | 6.19% | 0.66x | 1.45x | CN¥-40.59 Million |
| 2013 | 1.06% | 0.88% | 0.73x | 1.65x | CN¥-88.24 Million |
| 2014 | 2.22% | 1.85% | 0.80x | 1.50x | CN¥-78.34 Million |
| 2015 | 4.86% | 5.43% | 0.64x | 1.41x | CN¥-72.79 Million |
| 2016 | 6.15% | 4.32% | 0.86x | 1.66x | CN¥-57.83 Million |
| 2017 | 8.79% | 5.15% | 0.96x | 1.77x | CN¥-19.67 Million |
| 2018 | 8.33% | 4.74% | 0.91x | 1.92x | CN¥-29.13 Million |
| 2019 | 11.07% | 5.93% | 0.72x | 2.58x | CN¥18.76 Million |
| 2020 | 12.97% | 6.84% | 0.84x | 2.25x | CN¥61.33 Million |
| 2021 | 12.62% | 7.21% | 0.82x | 2.14x | CN¥72.97 Million |
| 2022 | 13.71% | 6.89% | 0.91x | 2.19x | CN¥117.55 Million |
| 2023 | 13.82% | 6.98% | 0.80x | 2.46x | CN¥132.68 Million |
| 2024 | 3.02% | 1.34% | 0.78x | 2.90x | CN¥-216.90 Million |
| 2025 | 10.73% | 5.54% | 0.69x | 2.80x | CN¥24.73 Million |
Industry Comparison
This section compares Chenguang Biotech Group's net assets metrics with peer companies in the Farm Products industry.
Industry Context
- Industry: Farm Products
- Average net assets among peers: $912,217,488
- Average return on equity (ROE) among peers: 12.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chenguang Biotech Group (300138) | CN¥3.46 Billion | 13.17% | 1.78x | $890.73 Million |
| ShenZhen Kondarl Group Co Ltd (000048) | $341.57 Million | 10.73% | 1.99x | $1.05 Billion |
| Guangdong Guanghong Holdings Co Ltd (000529) | $3.17 Billion | 6.71% | 1.21x | $391.26 Million |
| Hunan Zhenghong Science and Technology Develop Co Ltd (000702) | $300.43 Million | -21.72% | 1.35x | $249.55 Million |
| Hefei Fengle Seed Co Ltd (000713) | $1.12 Billion | 8.62% | 0.69x | $634.25 Million |
| Luoniushan Co Ltd (000735) | $418.09 Million | 11.68% | 0.34x | $850.94 Million |
| New Hope Liuhe Co Ltd (000876) | $1.84 Billion | 6.76% | 0.76x | $4.67 Billion |
| Yuan Longping High-tech Agriculture Co Ltd (000998) | $87.24 Million | 31.20% | 1.05x | $1.74 Billion |
| Dongrui Food Group Co Ltd (001201) | $569.61 Million | 45.97% | 0.50x | $584.69 Million |
| Jiangxi Sunshine Dairy Co Ltd (001318) | $585.62 Million | 19.17% | 0.10x | $589.82 Million |
| Shandong Denghai Seeds Co Ltd (002041) | $694.16 Million | 0.82% | 0.25x | $1.13 Billion |
About Chenguang Biotech Group
ChenGuang Biotech Group Co., Ltd. develops and produces natural colors, spice extracts and essential oils, nutritional and pharmaceutical extracts, and oils and protein. The company offers natural colors, including paprika oleoresin, marigold oleoresin, and turmeric; spice extracts and essential oils, such as capsicum oleoresin, sichuan pepper oil, pepper oleoresin, ginger extract, and cumin oleo… Read more